Published on 21/12/2025
Global Regulatory Requirements for Phase 4 Clinical Trials: A Country-by-Country Guide
Why Regulatory Oversight in Phase 4 Is Critical
Once a product receives regulatory approval and enters the market, its journey doesn’t end—rather, it transitions into a new phase: post-marketing surveillance, or Phase 4. Regulatory agencies across the globe require continued evaluation of a product’s safety, efficacy, and use in diverse populations. These studies are governed by varying regional regulations but share a common goal—ensuring that public health remains protected beyond clinical trial settings.
Understanding these expectations is essential for pharmaceutical sponsors, CROs, and clinical professionals aiming to remain compliant across multiple regulatory jurisdictions.
1. United States – U.S. Food and Drug Administration (FDA)
Key Guidelines:
- 21 CFR 314 Subpart H (Accelerated Approval)
- FDA Postmarketing Requirements and Commitments (PMRs and PMCs)
Expectations:
- PMRs: Legally enforceable studies required post-approval
- PMCs: Voluntary commitments by sponsors to generate additional data
- REMS: Risk Evaluation and Mitigation Strategy plans for products with safety concerns
- IND exemption: Some Phase 4 studies may be conducted without an IND if marketed doses are used
Oversight Tools:
- SENTINEL Initiative – a large-scale real-world evidence platform
- FAERS – Adverse Event Reporting System
2. European Union – European Medicines Agency (EMA)
Key Guidelines:
- Good Pharmacovigilance
Expectations:
- PASS: Post-Authorisation Safety Studies may be imposed (category 1) or voluntary (category 3)
- PAES: Post-Authorisation Efficacy Studies may be required for conditional or exceptional approvals
- All post-marketing studies must comply with GDPR for patient data use
Oversight Tools:
- EudraVigilance system for pharmacovigilance
- EU PAS Register for transparency and tracking
3. India – Central Drugs Standard Control Organization (CDSCO)
Key Guidelines:
- New Drugs and Clinical Trial Rules, 2019
- Schedule Y of Drugs and Cosmetics Act
Expectations:
- Post-marketing surveillance (PMS) is mandatory for new drugs in the first 2 years of approval
- Periodic Safety Update Reports (PSURs) must be submitted every 6 months for the first 2 years
- Form 44 and Form CT-14 to be used for post-marketing trial approvals
- Ethics Committee approval is mandatory even for observational PMS studies
4. Japan – Pharmaceuticals and Medical Devices Agency (PMDA)
Key Guidelines:
- Good Post-marketing Study Practice (GPSP)
- Japanese GCP and Risk Management Plans (RMPs)
Expectations:
- Mandatory submission of RMPs detailing safety measures and post-marketing study design
- Studies may be required as part of conditional early approval
- Annual safety reports and periodic submission of study progress to PMDA
5. Canada – Health Canada
Key Guidelines:
- Food and Drug Regulations – Division 8
- Guidance Document for Post-Market Surveillance
Expectations:
- Risk Management Plans: Required in alignment with ICH E2E
- Voluntary vs. Required post-approval studies based on submission class
- Mandatory reporting of serious adverse drug reactions (SADRs) and foreign actions
6. Australia – Therapeutic Goods Administration (TGA)
Expectations:
- Requires PSURs every 6 months for 2 years post-approval
- Accepts RMPs aligned with EMA templates
- May require Phase 4 studies to remain in ARTG (Australian Register of Therapeutic Goods)
Common Global Trends in Phase 4 Regulation
- Greater use of real-world evidence (RWE): Especially in rare disease and oncology settings
- Increased transparency: Global registries like EU PAS and ClinicalTrials.gov track post-marketing commitments
- Cross-border harmonization: ICH E2E, E2F, and E3 guidelines adopted by many agencies
Industry Considerations for Compliance
- Track regulatory timelines and PSUR/PBRER submission schedules
- Plan integrated RMP strategies during Phase 2/3 for smoother transitions
- Use global pharmacovigilance platforms to streamline data capture
- Ensure site SOPs reflect regional ethics and reporting guidelines
Final Thoughts
Regulatory expectations for Phase 4 trials vary globally, but all emphasize safety monitoring, risk management, and data-driven decision-making. Staying informed on each country’s guidelines ensures your studies remain compliant and impactful post-approval. Sponsors must build Phase 4 readiness into their clinical and regulatory strategies well before Phase 3 concludes.
At ClinicalStudies.in, we guide researchers through the complex landscape of post-marketing compliance—from PMS setup to global submissions.